Literature DB >> 34131743

Reimagining pilocytic astrocytomas in the context of pediatric low-grade gliomas.

Till Milde1,2,3, Fausto J Rodriguez4, Jill S Barnholtz-Sloan5,6,7, Nirav Patil6,7, Charles G Eberhart4, David H Gutmann8.   

Abstract

Pediatric low-grade gliomas (pLGGs) are the most common brain tumor in children and are associated with lifelong clinical morbidity. Relative to their high-grade adult counterparts or other malignant childhood brain tumors, there is a paucity of authenticated preclinical models for these pLGGs and an incomplete understanding of their molecular and cellular pathogenesis. While large-scale genomic profiling efforts have identified the majority of pathogenic driver mutations, which converge on the MAPK/ERK signaling pathway, it is now appreciated that these events may not be sufficient by themselves for gliomagenesis and clinical progression. In light of the recent World Health Organization reclassification of pLGGs, and pilocytic astrocytoma (PA), in particular, we review our current understanding of these pediatric brain tumors, provide a conceptual framework for future mechanistic studies, and outline the challenges and pressing needs for the pLGG clinical and research communities.
© The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  zzm321990 BRAFzzm321990 ; MEK; cellular senescence; low-grade glioma; neurofibromatosis type 1; pediatric brain tumor; pilocytic astrocytoma; tumor microenvironment

Mesh:

Year:  2021        PMID: 34131743      PMCID: PMC8485452          DOI: 10.1093/neuonc/noab138

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   13.029


  94 in total

1.  Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis.

Authors:  Michael J Fisher; Michael Loguidice; David H Gutmann; Robert Listernick; Rosalie E Ferner; Nicole J Ullrich; Roger J Packer; Uri Tabori; Robert O Hoffman; Simone L Ardern-Holmes; Trent R Hummel; Darren R Hargrave; Eric Bouffet; Joel Charrow; Larissa T Bilaniuk; Laura J Balcer; Grant T Liu
Journal:  Neuro Oncol       Date:  2012-04-03       Impact factor: 12.300

2.  Accurate calling of KIAA1549-BRAF fusions from DNA of human brain tumours using methylation array-based copy number and gene panel sequencing data.

Authors:  Damian Stichel; Daniel Schrimpf; Philipp Sievers; Annekathrin Reinhardt; Abigail K Suwala; Martin Sill; David E Reuss; Andrey Korshunov; Belén M Casalini; Alexander C Sommerkamp; Jonas Ecker; Florian Selt; Dominik Sturm; Astrid Gnekow; Arend Koch; Michèle Simon; Pablo Hernáiz Driever; Ulrich Schüller; David Capper; Cornelis M van Tilburg; Olaf Witt; Till Milde; Stefan M Pfister; David T W Jones; Andreas von Deimling; Felix Sahm; Annika K Wefers
Journal:  Neuropathol Appl Neurobiol       Date:  2021-01-17       Impact factor: 8.090

3.  Phase II Weekly Vinblastine for Chemotherapy-Naïve Children With Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study.

Authors:  Alvaro Lassaletta; Katrin Scheinemann; Shayna M Zelcer; Juliette Hukin; Beverley A Wilson; Nada Jabado; Anne Sophie Carret; Lucie Lafay-Cousin; Valerie Larouche; Cynthia E Hawkins; Gregory Russell Pond; Ken Poskitt; Daniel Keene; Donna L Johnston; David D Eisenstat; Rahul Krishnatry; Matthew Mistry; Anthony Arnoldo; Vijay Ramaswamy; Annie Huang; Ute Bartels; Uri Tabori; Eric Bouffet
Journal:  J Clin Oncol       Date:  2016-10-10       Impact factor: 44.544

4.  Pediatric glioma-associated KIAA1549:BRAF expression regulates neuroglial cell growth in a cell type-specific and mTOR-dependent manner.

Authors:  Aparna Kaul; Yi-Hsien Chen; Ryan J Emnett; Sonika Dahiya; David H Gutmann
Journal:  Genes Dev       Date:  2012-11-14       Impact factor: 11.361

5.  BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas.

Authors:  Stefan Pfister; Wibke G Janzarik; Marc Remke; Aurélie Ernst; Wiebke Werft; Natalia Becker; Grischa Toedt; Andrea Wittmann; Christian Kratz; Heike Olbrich; Rezvan Ahmadi; Barbara Thieme; Stefan Joos; Bernhard Radlwimmer; Andreas Kulozik; Torsten Pietsch; Christel Herold-Mende; Astrid Gnekow; Guido Reifenberger; Andrey Korshunov; Wolfram Scheurlen; Heymut Omran; Peter Lichter
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808

6.  Epidemiology of brainstem high-grade gliomas in children and adolescents in the United States, 2000-2017.

Authors:  Nirav Patil; Michael E Kelly; Debra Nana Yeboa; Robin A Buerki; Gino Cioffi; Sweta Balaji; Quinn T Ostrom; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2021-06-01       Impact factor: 12.300

7.  The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.

Authors:  Anne C Solga; Joseph A Toonen; Yuan Pan; Patrick J Cimino; Yu Ma; Guillaume A Castillon; Scott M Gianino; Mark H Ellisman; Da Yong Lee; David H Gutmann
Journal:  Oncotarget       Date:  2017-07-18

8.  MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism.

Authors:  Pratiti Bandopadhayay; Lori A Ramkissoon; Payal Jain; Guillaume Bergthold; Jeremiah Wala; Rhamy Zeid; Steven E Schumacher; Laura Urbanski; Ryan O'Rourke; William J Gibson; Kristine Pelton; Shakti H Ramkissoon; Harry J Han; Yuankun Zhu; Namrata Choudhari; Amanda Silva; Katie Boucher; Rosemary E Henn; Yun Jee Kang; David Knoff; Brenton R Paolella; Adrianne Gladden-Young; Pascale Varlet; Melanie Pages; Peleg M Horowitz; Alexander Federation; Hayley Malkin; Adam A Tracy; Sara Seepo; Matthew Ducar; Paul Van Hummelen; Mariarita Santi; Anna Maria Buccoliero; Mirko Scagnet; Daniel C Bowers; Caterina Giannini; Stephanie Puget; Cynthia Hawkins; Uri Tabori; Almos Klekner; Laszlo Bognar; Peter C Burger; Charles Eberhart; Fausto J Rodriguez; D Ashley Hill; Sabine Mueller; Daphne A Haas-Kogan; Joanna J Phillips; Sandro Santagata; Charles D Stiles; James E Bradner; Nada Jabado; Alon Goren; Jacques Grill; Azra H Ligon; Liliana Goumnerova; Angela J Waanders; Phillip B Storm; Mark W Kieran; Keith L Ligon; Rameen Beroukhim; Adam C Resnick
Journal:  Nat Genet       Date:  2016-02-01       Impact factor: 38.330

9.  A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01.

Authors:  Sébastien Perreault; Valérie Larouche; Uri Tabori; Cynthia Hawkin; Sarah Lippé; Benjamin Ellezam; Jean-Claude Décarie; Yves Théoret; Marie-Élaine Métras; Serge Sultan; Édith Cantin; Marie-Ève Routhier; Maxime Caru; Geneviève Legault; Éric Bouffet; Lucie Lafay-Cousin; Juliette Hukin; Craig Erker; Nada Jabado
Journal:  BMC Cancer       Date:  2019-12-27       Impact factor: 4.430

10.  The histomolecular criteria established for adult anaplastic pilocytic astrocytoma are not applicable to the pediatric population.

Authors:  Albane Gareton; Arnault Tauziède-Espariat; Volodia Dangouloff-Ros; Alexandre Roux; Raphaël Saffroy; David Castel; Thomas Kergrohen; Fréderic Fina; Dominique Figarella-Branger; Mélanie Pagès; Franck Bourdeaut; François Doz; Stéphanie Puget; Christelle Dufour; Emmanuèle Lechapt; Fabrice Chrétien; Jacques Grill; Pascale Varlet
Journal:  Acta Neuropathol       Date:  2019-11-01       Impact factor: 17.088

View more
  1 in total

1.  MiR-1248: a new prognostic biomarker able to identify supratentorial hemispheric pediatric low-grade gliomas patients associated with progression.

Authors:  Giuseppina Catanzaro; Zein Mersini Besharat; Andrea Carai; Natalie Jäger; Elena Splendiani; Carole Colin; Agnese Po; Martina Chiacchiarini; Anna Citarella; Francesca Gianno; Antonella Cacchione; Evelina Miele; Francesca Diomedi Camassei; Marco Gessi; Luca Massimi; Franco Locatelli; David T W Jones; Dominique Figarella-Branger; Stefan M Pfister; Angela Mastronuzzi; Felice Giangaspero; Elisabetta Ferretti
Journal:  Biomark Res       Date:  2022-06-17
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.